Evidence map›Paper›PMID 23064293›Full record

Trial reportDiabetologia2013

Ephedrine activates brown adipose tissue in lean but not obese humans.

A L Carey, M F Formosa, B Van Every, D Bertovic, N Eikelis, G W Lambert, V Kalff, S J Duffy, M H Cherk, B A Kingwell

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01015794 (Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation), which is not on this map. Cited by 89 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 1 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01015794 nacompletednot on this map

Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation

TypeinterventionalSponsorBayside HealthRan2009Enrolled25ConditionsObesityArmsephedrine hydrochloride
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Increased brown adipose tissue oxidative capacity in cold-acclimated humans.The Journal of clinical endocrinology and metabolism · 2014
    Trial
  7. Review
  8. Advances in research on thermogenic substances.Journal of physiological anthropology · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Weighing in on the role of brown adipose tissue for treatment of obesity.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Review
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A L CareyMetabolic and Vascular Physiology Laboratory, Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road Central, Melbourne, VIC 8008, Australia. andrew.carey@bakeridi.edu.au
M F Formosa
B Van Every
D Bertovic
N Eikelis
G W Lambert
V Kalff
S J Duffy
M H Cherk
B A Kingwell
Baker Heart and Diabetes Institute · AUThe Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisBrown adipose tissue (BAT) activation increases energy consumption and may help in the treatment of obesity. Cold exposure is the main physiological stimulus for BAT thermogenesis and the sympathetic nervous system, which innervates BAT, is essential in this process. However, cold-induced BAT activation is impaired in obese humans. To explore the therapeutic potential of BAT, it is essential to determine whether pharmacological agents can activate BAT.

methodsWe aimed to determine whether BAT can be activated in lean and obese humans after acute administration of an orally bioavailable sympathomimetic. In a randomised, double-blinded, crossover trial, we administered 2.5 mg/kg of oral ephedrine to nine lean (BMI 22 ± 1 kg/m²) and nine obese (BMI 36 ± 1 kg/m²) young men. On a separate day, a placebo was administered to the same participants. BAT activity was assessed by measuring glucose uptake with [¹⁸F]fluorodeoxyglucose and positron emission tomography-computed tomography imaging.

resultsBAT activity was increased by ephedrine compared with placebo in the lean, but unchanged in the obese, participants. The change in BAT activity after ephedrine compared with placebo was negatively correlated with various indices of body fatness. CONCLUSIONS/

interpretationBAT can be activated via acute, oral administration of the sympathomimetic ephedrine in lean, but not in obese humans.

Indexed as

Adipose Tissue, BrownAdrenergic AgentsAdultBiological TransportBody Mass IndexCalorimetry, IndirectCross-Over StudiesDouble-Blind MethodEphedrineFluorodeoxyglucose F18GlucoseHumansMaleMultimodal ImagingObesityPositron-Emission TomographyAdrenergic AgentsEphedrineFluorodeoxyglucose F18GlucoseSympathomimetics

Identifiers

PMID23064293
OpenAlexW2026952221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.